  0086-574-87934126
Home / News

News and Events

  • Sources of Impurities in Pharmaceutical Substances


    The origin of impurities in drugs is from various sources and phases if the synthetic process and preparation of pharmaceutical dosage forms. Majority of the impurities are characteristics of the synthetic route of the manufacturing process. There are several possibilities of synthesizing a drug; it is possible that the same product of different sources may give rise to different impurities. Read More

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates


    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts. Read More

  • Development Trend of China's Pharmaceutical Intermediate Industry


    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. Read More

  • Intermediates of Eribulin Mesylate


    Eribulin is a chemotherapy drug. Its full name is eribulin mesylate. Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Read More

  • Prostate Cancer and Darolutamide


    Darolutamide was approved by FDA on Jul 30, 2019, and approved by the EMA on March 27, 2020, the trade name is Nubeqa. The drug was research by Orinon, the on Jun 2014, Bayer got the global development and commercial right in the world. Its molecular conformation is different from Enzalutamide and Apalutamide, and its unique chemical structure enables this drug to inhibit the growth of cancer cells by blocking the function of androgen receptors by blocking nuclear ectopic. Read More

  • Bosutinib CAS 380843-75-4


    Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012. Read More

  • How is a drug produced?


    There are so many different drugs ,with different color /shape ( like capsule ,tablet or Infusion) and price . Here we would like to explain , what makes it so different? How is a drug produced? Read More

  • What Is Olmesartan Medoxomil Used For?


    Olmesartan medoxomil is made because the prodrug olmesartan medoxomil that is apace reborn to the pharmacologically active olmesartan.1 it absolutely was developed by Daiichi Sankyo prescription drugs and approved in 2002. Read More

  • Edoxaban: an Anticoagulant Drug


    Edoxaban is the first oral anticoagulant on the market in Japan, and it is also the first time in the world. This product can inhibit thrombosis through selective, reversible and direct inhibition of FXa. Its good tolerance, oral absorption and anticoagulant activity have been verified by clinical development. Read More

  • Total 4 pages  Go to Page
  • Go
We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API.



 Tel: 0086-574-87934126
 Cell: 0086-13600625331
 Fax: 0086-574-87994093
 Whatsapp/Wechat: 0086-13600625331
 Email: info@sandoopharm.com
 Add: 9th Floor, 1#,Smart park, No.98 Chuangyuan Rd, Ningbo, Zhejiang, China


© 2020 Sandoo Pharmaceuticals and Chemicals Co., Ltd. All rights reserved.